HER-2/neu expression in lesions of uterine cervix: Is it reliable and consistent?
Author(s) -
Sanjay Kumar,
Nidhi Gupta,
Sunita Singh,
Nisha Marwah,
Sonia Chabra,
Rajeev Sen
Publication year - 2009
Publication title -
indian journal of pathology and microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.217
H-Index - 31
eISSN - 0974-5130
pISSN - 0377-4929
DOI - 10.4103/0377-4929.56127
Subject(s) - pathology , malignancy , medicine , immunostaining , stage (stratigraphy) , cervix , adenocarcinoma , immunohistochemistry , cervical intraepithelial neoplasia , lymph node , carcinoma , oncogene , cervical cancer , cancer , biology , cell cycle , paleontology
This study was conducted to evaluate the expression of HER-2/neu oncogene in the lesions of the uterine cervix and to determine its correlation with histological type of malignancy, grade and clinical stage of presentation. One hundred cervical specimens were included in this study. These comprised cases with diagnosis of benign epithelial lesions, squamous cell carcinoma, adenocarcinoma, carcinoma cervix with glandular differentiation and cervical intraepithelial neoplasia. HER-2/neu immunostaining was performed by streptovidin-biotin peroxidase method. Higher expression of HER-2/neu was noted in malignant lesions as compared to benign lesions. Intensity of staining also correlated with clinical stage of presentation, lymph node metastasis and presence of parametrial extension. The over-expression of HER-2 oncoprotein is associated with poor prognosis, metastatic potential and aggressive biological behavior.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom